98%
921
2 minutes
20
Candida albicans Cdr1 is a plasma membrane ATP-binding cassette transporter encoded by CDR1 that was first cloned 30 years ago in Saccharomyces cerevisiae. Increased expression of Cdr1 in C. albicans clinical isolates results in resistance to azole antifungals due to drug efflux from the cells. Knowledge of Cdr1 structure and function could enable the design of Cdr1 inhibitors that overcome efflux-mediated drug resistance. This article reviews the use of expression systems to study Cdr1. Since the discovery of CDR1 in 1995, 123 studies have investigated Cdr1 using either heterologous or homologous expression systems. The majority of studies have employed integrative transformation and expression in S. cerevisiae. We describe a suite of plasmids with a range of useful protein tags for integrative transformation that enable the creation of tandem-gene arrays stably integrated into the S. cerevisiae genome, and a model for Cdr1 transport function. While expression in S. cerevisiae generates a strong phenotype and high yields of Cdr1, it is a nonnative environment and may result in altered structure and function. Membrane lipid composition and architecture affects membrane protein function and a focus on homologous expression in C. albicans may permit a more accurate understanding of Cdr1 structure and function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974388 | PMC |
http://dx.doi.org/10.1093/femsyr/foaf012 | DOI Listing |
Int Immunopharmacol
September 2025
Center for Genetic Engineering and Biotechnology, Cubanacan, 10600 Havana, POBox 6162, Cuba. Electronic address:
Vascular endothelial growth factor (VEGF) is a key player in the development and progression of several diseases, most notably cancer and retinal disorders. Over the last twenty years, VEGF has emerged as a significant therapeutic target for these conditions. This study reports the isolation and characterization of a fully synthetic, humanized, affinity-matured single-domain antibody fragment (VHH) designed to target VEGF.
View Article and Find Full Text PDFMicrobiology (Reading)
September 2025
Division of Oral Biosciences, Dublin Dental University Hospital, University of Dublin, Trinity College Dublin, Dublin, Ireland.
is an opportunistic fungal pathogen associated with superficial and systemic infections in humans. Azole antifungal resistance in is of clinical concern, and both oral and systemic infections can be difficult to treat due to the lack of alternative antifungal drugs. Expression of a hyperactive form of the transcription factor Tac1 is a major contributor to azole resistance in isolates resulting in the increased expression of the azole efflux pump Cdr1.
View Article and Find Full Text PDFSci Rep
August 2025
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Candida onychomycosis is a common fungal nail infection where treatment efficacy can be compromised by antifungal resistance. This study investigates the role of efflux pump genes (CDR1, CDR2, and MDR1) and biofilm-associated genes (ALS1, ALS3) in Candida albicans isolates classified as resistant to itraconazole from patients with onychomycosis. Ten itraconazole-resistant and 10 sensitive isolates were collected for efflux pump and biofilm-associated gene expression analysis by Real-Time PCR methods.
View Article and Find Full Text PDFAntimicrob Agents Chemother
August 2025
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
has emerged as a fungal pathogen of particular concern owing in part to its propensity to exhibit antifungal resistance, especially to the commonly prescribed antifungal fluconazole. A mutation in , which encodes a zinc cluster transcription factor, has been shown to confer increased resistance to fluconazole. In this work, we aimed to determine how mutations in exert this effect.
View Article and Find Full Text PDFProteins
August 2025
Department of Physical and Chemical Sciences, University of L'aquila, L'Aquila, Italy.
The advancement of T cell engineering has significantly transformed the field of cancer immunotherapy. In particular, T cells equipped with modified T cell receptors present a promising therapeutic strategy, especially for addressing solid tumors. Nonetheless, critical obstacles, including suboptimal clinical response rates, off-target toxicity, and the immunosuppressive nature of the tumor microenvironment, have impeded the full clinical implementation of this approach.
View Article and Find Full Text PDF